Patents by Inventor Mandy A. C. Jongeneelen

Mandy A. C. Jongeneelen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
    Patent number: 9611317
    Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 4, 2017
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Robert H. E. Friesen, Theodorus H. J. Kwaks, Mandy A. C. Jongeneelen
  • HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF
    Publication number: 20150175677
    Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Application
    Filed: May 20, 2013
    Publication date: June 25, 2015
    Inventors: Mark Throsby, Robert H.E. Friesen, Theodorus H.J. Kwaks, Mandy A. C. Jongeneelen
  • HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF
    Publication number: 20130309248
    Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 21, 2013
    Inventors: Mark Throsby, Robert H.E. Friesen, Theodorus H.J. Kwaks, Mandy A. C. Jongeneelen